

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6904504

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	JANSSEN RESEARCH & DEVELOPMENT, LLC	02/15/2021
RECEIVING PARTY DATA		
Name:	ACTELION PHARMACEUTICALS LTD	
Street Address:	GEWERBESTRASSE 16	
City:	ALLSCHWIL	
State/Country:	SWITZERLAND	
Postal Code:	4123	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	17189881
CORRESPONDENCE DATA		
Fax Number:	(215)568-3439	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2155683100	
Email:	patents@bakerlaw.com	
Correspondent Name:	BAKER & HOSTETLER LLP	
Address Line 1:	2929 ARCH STREET	
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19104-2891	
ATTORNEY DOCKET NUMBER:	103693.001984	
NAME OF SUBMITTER:	DENISE MARVEL	
SIGNATURE:	/Denise Marvel/	
DATE SIGNED:	09/08/2021	
Total Attachments: 1		
source=JRD_to_ACT_Assignment#page1.tif		

General Assignment

WHEREAS, **Janssen Research & Development, LLC**, having its place of business at 920 US Route 202, PO Box 300, Raritan NJ 08869, USA (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

"PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION"

for which on the 20th day of December 2019, International Patent Application no. PCT/EP2019/086754 was filed at the European Patent Office.

WHEREAS, Actelion Pharmaceuticals Ltd, having its place of business at Gewerbestrasse 16, 4123 Allschwil, Switzerland (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,

NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.


And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 21st day of December 2018.

IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.


For Janssen Research & Development LLC

For Actelion Pharmaceuticals Ltd


Authorized Signatory

For Janssen Research & Development LLC

Signature Date :


Authorized Signatory

For Actelion Pharmaceuticals Ltd

Signature Date : 7.4.2021

15- FEB - 2021
Dr. Frank Schager **Eric Ruhlmann**
European Patent Attorney European Patent Attorney
Chief Patent Counsel Senior Patent Counsel

PATENT